Month: July 2024

July 2, 2024 Biodexa Pharmaceuticals PLC Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024 After Only Two Infusions and Two Patients at Optimal Dose, Median Overall Survival Across all Patients was 16.5 Months (vs 10.0 Months in Historical Reference Cohort) (DATELINE) JULY 2 — Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces data from a Phase 1 study of MTX110 in Diffuse Midline Glioma (“DMG”) f/k/a Diffuse Intrinsic Pontine Glioma, or DIPG, an orphan pediatric brain cancer were presented over the weekend at the 21st International Symposium on Pediatric Neuro-Oncology...

RIMOUSKI, Quebec, July 02, 2024 (GLOBE NEWSWIRE) — Puma Exploration Inc. (TSXV: PUMA, OTCQB: PUMXF) (the “Company” or “Puma”) is pleased to provide an update on its sale agreements with Raptor Resources Ltd. (“Raptor”) and Canadian Copper Inc. (“Canadian Copper”) respecting the sale and transfer to Raptor of the Chester and Turgeon Projects (see Figure 1) located in New Brunswick, Canada for a total possible consideration of AUD$2,000,000 in cash and shares as outlined in its March 4, 2024, News Release. Raptor has recently informed Puma and Canadian Copper that the prospectus relating to its initial public offering of at least AUD$10,000,000 will be lodged with the Australian Securities Exchange (“ASX”) on or before July 15, 2024. Pursuant to the sale agreement on Chester, Raptor was required to prepare and lodge a prospectus...

WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has completed the resubmission of its Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for cosibelimab, its anti-programmed death ligand-1 (“PD-L1”) antibody, as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”) who are not candidates for curative surgery or curative radiation. The BLA resubmission follows Checkpoint recently reaching alignment with the FDA on its BLA resubmission strategy to potentially address all approvability deficiencies outlined in the complete response letter (“CRL”) received last December, in which FDA only cited...

TORONTO, July 02, 2024 (GLOBE NEWSWIRE) — Probe Gold Inc. (TSX: PRB) (OTCQB: PROBF) (“Probe” or the “Company”) is pleased to announce the appointment of Marc Ducharme as Vice President of Exploration, effective immediately. Mr. Marc Ducharme is an exploration geologist with over 35 years of experience in geology, mineral, and mining exploration. He has extensive experience in the Abitibi region of Quebec, as well as experience in Ontario and on international projects. He has a proven track record in managing and executing exploration programs, from initial stages to advanced levels, and has extensive experience in overseeing mine site geology for both underground and open pit gold mines. He has been involved with the discovery of several new gold deposits and the expansion of numerous mineralized zones, most notably Wesdome’s Kiena...

PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts summarizing clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 “SHINE” study of CT1812 have been accepted for poster presentation at the upcoming Alzheimer’s Association’s International Conference being held in Philadelphia, PA from July 28-August 1, 2024. AAIC Presentation detailsAbstract #89115: Clinical Efficacy Results from COG0201: a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Adults with Mild-to-Moderate Alzheimer’s Disease Abstract #95147: CSF Phosphoproteomics Biomarker Analysis from the Phase 2 Clinical...

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be hosting one-on-one meetings with institutional investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, being held on July 9 and 10, 2024 in Boston, MA. The event will feature analyst-hosted panel discussions with leading physicians in a range of autoimmune and metabolic indications, as well as meetings between participating companies and investors. About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For...

The initial system integration in a vehicle has been completed, along with the first prototype tests of BlincVision in a vehicle outdoors. These tests mark a significant step forward in the development process toward a finished product. The next step is to extend the prototype testing during the summer with evaluations on an authorized test track. This will be done to evaluate the system’s functionality under more realistic and situational conditions and to test according to standardized Euro NCAP test methods for ADAS systems. The test track AstaZero offers a customizable environment where buildings, vehicles, people, and other objects can be arranged to create realistic traffic situations, and where brake tests can be performed at higher speeds. This allows Terranet to systematically analyze how BlincVision reacts in various situations...

“Imagine: A Musical Collaboration with Jeremy Renner,” premieres at the opening night of Artown, a 31-day celebration held annually in Reno, Nevada, and the largest arts and culture festival in the western United States. In collaboration with the RennerVation Foundation and Big Brothers Big Sisters of Northern Nevada, six youth ages 14 to 16 worked with The John Lennon Educational Tour Bus to write, record and produce an original song and accompanying music video. The RennerVation Foundation, founded in Reno, Nevada, was established to offer children in foster care and at-risk youth the chance to embrace a childhood filled with opportunity, growth, and belonging. The project was hosted by Dragonfly Energy as part of their support of the John Lennon Educational Tour Bus, which is powered by Dragonfly Energy’s Battle Born Batteries. The...